Zeidan, A., Ando, K., Rauzy, O., Turgut, M., Wang, M., Cairoli, R., et al. (2022). Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS). Intervento presentato a: 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH) - DEC 10-13, 2022, New Orleans, USA [10.1182/blood-2022-158612].
Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
Cairoli, R;
2022
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Zeidan-2022-Blood-VoR.pdf
Solo gestori archivio
Descrizione: Abstract
Tipologia di allegato:
Publisher’s Version (Version of Record, VoR)
Licenza:
Tutti i diritti riservati
Dimensione
769.82 kB
Formato
Adobe PDF
|
769.82 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
